BSE:506197

Stock Analysis Report

Executive Summary

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Bliss GVS Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

20.0%

506197

2.8%

IN Pharmaceuticals

3.3%

IN Market


1 Year Return

-24.5%

506197

-17.2%

IN Pharmaceuticals

7.1%

IN Market

Return vs Industry: 506197 underperformed the Indian Pharmaceuticals industry which returned -17.2% over the past year.

Return vs Market: 506197 underperformed the Indian Market which returned 7.1% over the past year.


Shareholder returns

506197IndustryMarket
7 Day20.0%2.8%3.3%
30 Day21.7%-4.4%2.9%
90 Day-18.3%-1.9%3.1%
1 Year-23.8%-24.5%-16.5%-17.2%9.4%7.1%
3 Year-23.5%-24.8%-25.6%-27.1%22.7%16.4%
5 Year85.6%80.7%-10.3%-13.0%44.0%30.4%

Price Volatility Vs. Market

How volatile is Bliss GVS Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bliss GVS Pharma undervalued compared to its fair value and its price relative to the market?

11x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 506197 (₹127.05) is trading above our estimate of fair value (₹14.53)

Significantly Below Fair Value: 506197 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 506197 is good value based on its PE Ratio (11x) compared to the Pharmaceuticals industry average (15.8x).

PE vs Market: 506197 is good value based on its PE Ratio (11x) compared to the Indian market (13x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 506197's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 506197 is overvalued based on its PB Ratio (2x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Bliss GVS Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

2.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 506197's forecast earnings growth (2.8% per year) is below the savings rate (7.6%).

Earnings vs Market: 506197's earnings (2.8% per year) are forecast to grow slower than the Indian market (18.3% per year).

High Growth Earnings: 506197's earnings are forecast to grow, but not significantly.

Revenue vs Market: 506197's revenue (13.6% per year) is forecast to grow faster than the Indian market (11.3% per year).

High Growth Revenue: 506197's revenue (13.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 506197's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bliss GVS Pharma performed over the past 5 years?

7.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 506197's earnings have grown by 7.1% per year over the past 5 years.

Accelerating Growth: 506197's earnings growth over the past year (154.3%) exceeds its 5-year average (7.1% per year).

Earnings vs Industry: 506197 earnings growth over the past year (154.3%) exceeded the Pharmaceuticals industry 14.2%.


Return on Equity

High ROE: 506197's Return on Equity (18.3%) is considered low.


Return on Assets

ROA vs Industry: 506197 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 506197's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Bliss GVS Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 506197's short term assets (₹6.9B) exceeds its short term liabilities (₹2.1B)

Long Term Liabilities: 506197's short term assets (6.9B) exceeds its long term liabilities (379.9M)


Debt to Equity History and Analysis

Debt Level: 506197's debt to equity ratio (14.7%) is considered satisfactory

Reducing Debt: 506197's debt to equity ratio has reduced from 54.5% to 14.7% over the past 5 years.

Debt Coverage: 506197's debt is well covered by operating cash flow (41.3%).

Interest Coverage: 506197's interest payments on its debt are well covered by EBIT (38.6x coverage).


Balance Sheet

Inventory Level: 506197 has a high level of physical assets or inventory.

Debt Coverage by Assets: 506197's debt is covered by short term assets (assets are 7.162990x debt).


Next Steps

Dividend

What is Bliss GVS Pharma's current dividend yield, its reliability and sustainability?

0.79%

Current Dividend Yield


Dividend Yield vs Market

company0.8%marketbottom25%0.6%markettop25%2.4%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 506197's dividend (0.79%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 506197's dividend (0.79%) is low compared to the top 25% of dividend payers in the Indian market (2.42%).

Stable Dividend: 506197's dividend payments have been volatile in the past 10 years.

Growing Dividend: 506197's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (8.7%), 506197's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Bliss GVS Pharma's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

Shibroor Kamath (66yo)

13.4yrs

Tenure

₹19,778,000

Compensation

Mr. Shibroor Narasimha Kamath has been the Managing Director of Bliss Gvs Pharma Limited (formerly, Bliss Chemicals & Pharmaceuticals India Ltd) since May 9, 2006 and serves as its Chief executive Officer  ...


CEO Compensation Analysis

Compensation vs. Market: Shibroor's total compensation ($USD278.26K) is about average for companies of similar size in the Indian market ($USD282.46K).

Compensation vs Earnings: Shibroor's compensation has increased by more than 20% in the past year.


Management Age and Tenure

4.2yrs

Average Tenure

36yo

Average Age

Experienced Management: 506197's management team is considered experienced (4.2 years average tenure).


Board Age and Tenure

9.8yrs

Average Tenure

59yo

Average Age

Experienced Board: 506197's board of directors are considered experienced (9.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sell₹559,394,28504 Feb 19
Shibroor Kamath
EntityIndividual
Role
Chief Executive Officer
CEO, MD & Executive Director
Shares3,660,000
Max Price₹152.84
Sell₹284,846,64704 Feb 19
Gautam Ashra
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares1,861,743
Max Price₹153.00

Ownership Breakdown


Management Team

  • Shibroor Kamath (66yo)

    CEO, MD & Executive Director

    • Tenure: 13.4yrs
    • Compensation: ₹19.78m
  • Vipul Thakkar (36yo)

    Chief Financial Officer

    • Tenure: 4.2yrs
    • Compensation: ₹2.47m
  • Vibha Sharma (36yo)

    Executive & Whole Time Director

    • Tenure: 11.3yrs
    • Compensation: ₹4.45m
  • Shruti N. Rao (34yo)

    Executive & Whole Time Director

    • Tenure: 13.3yrs
    • Compensation: ₹4.45m
  • Aditi Bhatt

    Compliance Officer & Company Secretary

    • Tenure: 1.2yrs
    • Compensation: ₹719.80k

Board Members

  • Gautam Ashra (63yo)

    Non-Executive Director

    • Tenure: 15.3yrs
    • Compensation: ₹150.00k
  • Shibroor Kamath (66yo)

    CEO, MD & Executive Director

    • Tenure: 13.4yrs
    • Compensation: ₹19.78m
  • Vibha Sharma (36yo)

    Executive & Whole Time Director

    • Tenure: 11.3yrs
    • Compensation: ₹4.45m
  • Shruti N. Rao (34yo)

    Executive & Whole Time Director

    • Tenure: 13.3yrs
    • Compensation: ₹4.45m
  • Mayank Mehta (59yo)

    Independent Chairman of the Board

    • Tenure: 4.4yrs
    • Compensation: ₹150.00k
  • Subramanian Vaidya (77yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: ₹120.00k
  • Santosh Parab (49yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: ₹150.00k

Company Information

Bliss GVS Pharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bliss GVS Pharma Limited
  • Ticker: 506197
  • Exchange: BSE
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹13.105b
  • Shares outstanding: 103.15m
  • Website: https://www.blissgvs.com

Location

  • Bliss GVS Pharma Limited
  • 102, Hyde Park
  • Saki Vihar Road
  • Mumbai
  • Maharashtra
  • 400072
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
506197BSE (Mumbai Stock Exchange)YesEquity SharesININRJan 2002
BLISSGVSNSEI (National Stock Exchange of India)YesEquity SharesININRJan 2002

Biography

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 12:40
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.